Insmed Incorporated (NASDAQ:INSM) Insider Sells $2,674,149.50 in Stock

Insmed Incorporated (NASDAQ:INSM) insider Martina M.D. Flammer sold 33,055 shares of the stock in a transaction dated Thursday, February 6th. The stock was sold at an average price of $80.90, for a total value of $2,674,149.50. Following the sale, the insider now owns 138,053 shares of the company’s stock, valued at $11,168,487.70. This represents a 19.32 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Martina M.D. Flammer also recently made the following trade(s):

• On Tuesday, January 14th, Martina M.D. Flammer sold 1,384 shares of Insmed stock. The stock was sold at an average price of $68.72, for a total value of $95,108.48.
• On Friday, January 10th, Martina M.D. Flammer sold 6,172 shares of Insmed stock. The shares were sold at an average price of $63.64, for a total transaction of $392,786.08.
• On Tuesday, January 7th, Martina M.D. Flammer sold 3,344 shares of Insmed stock. The shares were sold at an average price of $65.91, for a total transaction of $220,403.04.

Insmed Stock Performance

Shares of NASDAQ:INSM opened at $79.95 on Monday. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. Insmed Incorporated has a 12 month low of $21.92 and a 12 month high of $82.04. The company has a market capitalization of $14.30 billion, a price-to-earnings ratio of -14.41 and a beta of 1.11. The firm’s 50-day moving average is $72.88 and its 200 day moving average is $73.09.

Analysts Set New Price Targets

INSM has been the topic of several research analyst reports. HC Wainwright reiterated a “buy” rating and issued a $90.00 price target on shares of Insmed in a research note on Friday, November 1st. JPMorgan Chase & Co. boosted their target price on Insmed from $83.00 to $92.00 and gave the stock an “overweight” rating in a research report on Friday. Truist Financial restated a “buy” rating and set a $105.00 price target (up previously from $100.00) on shares of Insmed in a report on Friday, November 1st. Morgan Stanley upped their price objective on Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a report on Thursday. Finally, Guggenheim raised their target price on shares of Insmed from $95.00 to $101.00 and gave the company a “buy” rating in a report on Friday. One investment analyst has rated the stock with a sell rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $85.00.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the business. Steward Partners Investment Advisory LLC lifted its stake in shares of Insmed by 65.2% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 163 shares during the last quarter. V Square Quantitative Management LLC purchased a new stake in Insmed in the third quarter worth $30,000. GAMMA Investing LLC lifted its position in shares of Insmed by 71.3% during the third quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 224 shares during the last quarter. Spire Wealth Management purchased a new stake in shares of Insmed during the fourth quarter valued at $47,000. Finally, Exchange Traded Concepts LLC grew its holdings in shares of Insmed by 522.5% in the third quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 627 shares during the last quarter.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.